HMGA2 and idiopathic pulmonary fibrosis: In addition to its role in the canonical pathway inhibiting TβRI and SMAD4 [43,78], miR-26a also targets high mobility group protein A2 (HMGA2), which is a key factor in EMT and is upregulated in IPF [79,80].